Key Concepts of Toll-Like Receptors

Why This Matters

Toll-like receptors (TLRs) are the immune system's first line of surveillance. They're the molecular sensors that distinguish "self" from "dangerous non-self." Understanding TLRs means understanding how your body decides to launch an immune response in the first place. You're being tested on pattern recognition, signal transduction, and the bridge between innate and adaptive immunity. These concepts appear repeatedly in questions about inflammation, cytokine production, and host-pathogen interactions.

Don't just memorize which TLR recognizes which ligand. Focus on why certain molecular patterns signal danger, how different signaling pathways produce different immune outputs, and when the system tips from protective response to pathological inflammation. Exam questions will ask you to connect receptor activation to downstream effects, so know the logic, not just the list.

---

Bacterial Cell Wall Recognition

TLRs evolved to detect conserved molecular structures called pathogen-associated molecular patterns (PAMPs) that pathogens can't easily change without losing function. Bacterial cell wall components are ideal targets because they're essential for bacterial survival and structurally distinct from anything in the human body.

TLR4 (Lipopolysaccharide Receptor)

• Recognizes lipopolysaccharide (LPS), the signature molecule of Gram-negative bacterial outer membranes. LPS doesn't bind TLR4 directly on its own; it first binds LPS-binding protein (LBP) in the serum, then transfers to CD14 on the cell surface, and finally is presented to the TLR4/MD-2 complex. This multi-step handoff is why LPS recognition is so sensitive.
• Triggers potent pro-inflammatory cytokine release through both MyD88 and TRIF pathways, making it uniquely versatile among TLRs.
• Mediates septic shock when overactivated. Massive Gram-negative bacteremia floods the blood with LPS, causing systemic TLR4 activation, a cytokine storm, and potentially fatal hypotension. This illustrates how protective immunity can become pathological.

TLR2 (Peptidoglycan Receptor)

• Detects peptidoglycan, lipoteichoic acid, and bacterial lipoproteins, components abundant in Gram-positive bacterial cell walls.
• Forms heterodimers with TLR1 or TLR6 to expand its recognition range. TLR2/TLR1 heterodimers recognize triacylated lipopeptides (common in Gram-negative bacteria and mycobacteria), while TLR2/TLR6 heterodimers recognize diacylated lipopeptides (common in mycoplasma and Gram-positive bacteria). This heterodimerization strategy lets a single receptor cover a broader set of microbial structures.
• Activates NF-κB signaling to drive antibacterial responses, particularly against staphylococci and streptococci.

TLR5 (Flagellin Receptor)

• Recognizes flagellin, the structural protein subunit of bacterial flagella in motile bacteria. TLR5 binds a conserved region of flagellin that is essential for flagellar function, so bacteria can't easily mutate away from detection without losing motility.
• Expressed on the basolateral surface of epithelial cells in the gut and respiratory tract, providing frontline surveillance. The basolateral positioning means TLR5 is activated mainly when bacteria breach the epithelial barrier, not by commensal organisms sitting in the lumen.
• Induces chemokine production that recruits neutrophils and other immune cells to infection sites.

---

Viral Nucleic Acid Detection

Viruses lack the distinctive cell wall structures of bacteria, so TLRs detect them through their genetic material. The key principle: viral nucleic acids often have features that mammalian nucleic acids lack or keep hidden. Double-stranded RNA, for instance, is a hallmark of viral replication that doesn't normally exist in the cytoplasm of healthy cells. Unmethylated CpG motifs are common in microbial genomes but heavily methylated in vertebrate DNA. The endosomal location of these TLRs adds another layer of discrimination: self nucleic acids are normally degraded before reaching endosomes, while viral nucleic acids arrive there through phagocytosis of viral particles.

TLR3 (Double-Stranded RNA Receptor)

• Recognizes dsRNA, a replication intermediate produced by many RNA viruses and a hallmark of viral infection. Even some DNA viruses generate dsRNA during transcription of convergent genes.
• Located in endosomes, where it encounters viral RNA after phagocytosis or autophagy of infected material. This compartmentalization prevents inappropriate activation by self RNA.
• Signals exclusively through TRIF (not MyD88), leading to robust type I interferon production via IRF3 activation. TLR3 is the only TLR that is entirely MyD88-independent.

TLR7 (Single-Stranded RNA Receptor)

• Detects ssRNA in endosomes, recognizing viruses like influenza, HIV, and SARS-CoV-2. TLR7 senses guanosine- and uridine-rich sequences that are characteristic of viral RNA.
• Triggers type I interferon production through MyD88-dependent activation of IRF7.
• Highly expressed in plasmacytoid dendritic cells (pDCs), the body's professional interferon-producing cells. pDCs can produce up to 1,000 times more type I interferon than other cell types, and TLR7 (along with TLR9) is central to this capacity.

TLR9 (CpG DNA Receptor)

• Recognizes unmethylated CpG dinucleotides, which are common in bacterial and viral DNA but rare and heavily methylated in vertebrate DNA. This methylation difference is the key discriminator.
• Activates both inflammatory cytokines and type I interferons, bridging antibacterial and antiviral responses.
• Critical for recognizing DNA viruses like herpes simplex virus. Also important in vaccine design: synthetic CpG oligonucleotides are used as adjuvants precisely because they activate TLR9 and boost adaptive immune responses.

---

Signaling Pathways and Adaptor Proteins

TLR activation is meaningless without signal transduction. The adaptor proteins MyD88 and TRIF determine whether TLR engagement produces inflammatory cytokines, antiviral interferons, or both. Think of them as two different wiring systems that connect the same type of receptor to very different outputs.

MyD88-Dependent Signaling Pathway

Here's how the MyD88 pathway works, step by step:

1. A TLR binds its ligand and dimerizes, bringing the intracellular TIR (Toll/IL-1 receptor) domains together.
2. MyD88 is recruited to the TIR domains via its own TIR domain.
3. MyD88 recruits IRAK4, which phosphorylates and activates IRAK1/2.
4. Activated IRAKs recruit TRAF6, which activates the TAK1 kinase complex.
5. TAK1 activates the IKK complex, which phosphorylates IκB, targeting it for proteasomal degradation.
6. Free NF-κB translocates to the nucleus and drives transcription of pro-inflammatory cytokines (IL-1, IL-6, TNF-α) and chemokines.

• Used by all TLRs except TLR3, making it the dominant TLR signaling route.
• Essential for acute inflammatory responses to bacterial infections. MyD88 deficiency in humans causes severe susceptibility to pyogenic (pus-forming) bacterial infections, especially in childhood.

TRIF-Dependent Signaling Pathway

1. TLR3 or TLR4 recruits TRIF (also called TICAM-1) to its TIR domain. For TLR4, the adaptor TRAM bridges TLR4 and TRIF.
2. TRIF activates TRAF3, which recruits and activates the kinases TBK1 and IKKε.
3. TBK1/IKKε phosphorylate IRF3, causing it to dimerize and translocate to the nucleus.
4. Nuclear IRF3 drives transcription of type I interferon genes (IFN-α, IFN-β).
5. TRIF also activates TRAF6, leading to delayed NF-κB activation (so TRIF can produce some inflammatory cytokines too, just more slowly).

• Activated by TLR3 and TLR4. TLR4 uniquely uses both pathways: MyD88 signaling occurs from the plasma membrane, while TRIF signaling occurs after TLR4 is endocytosed. This spatial separation allows TLR4 to generate two waves of signaling.
• Produces a slower but sustained response compared to MyD88, important for establishing antiviral states.

---

Downstream Effector Mechanisms

The ultimate goal of TLR signaling is gene expression changes that eliminate pathogens. Two major outputs dominate: NF-κB-driven inflammation and IRF-driven interferon production.

NF-κB Activation

• Master transcription factor for inflammation. NF-κB induces genes for pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), chemokines (IL-8/CXCL8), adhesion molecules, and antimicrobial peptides like defensins.
• Normally sequestered in the cytoplasm by IκB. TLR signaling triggers IκB phosphorylation, ubiquitination, and proteasomal degradation, freeing NF-κB to translocate to the nucleus.
• Dysregulated NF-κB activity underlies chronic inflammatory diseases (rheumatoid arthritis, inflammatory bowel disease) and contributes to some cancers by promoting cell survival and proliferation.

Type I Interferon Production

• Includes IFN-α and IFN-β, cytokines that establish an "antiviral state" in neighboring cells. They do this by inducing hundreds of interferon-stimulated genes (ISGs) that degrade viral RNA, inhibit viral protein synthesis, and promote apoptosis of infected cells.
• Induced primarily by TLR3, TLR7, TLR8, and TLR9 through IRF3 and IRF7 activation. IRF3 drives the initial wave of IFN-β; the secreted IFN-β then acts in an autocrine/paracrine manner to upregulate IRF7, which amplifies production of multiple IFN-α subtypes.
• Bridges innate and adaptive immunity by enhancing MHC class I expression, promoting dendritic cell maturation, activating NK cells, and supporting CD8+ T cell responses.

---

Quick Reference Table

---

Self-Check Questions

1. Which two TLRs both recognize viral RNA, and how do their ligands and signaling pathways differ?

2. TLR4 is unique among TLRs. What structural and signaling features make it distinct, and what are the functional consequences?

3. A patient has a MyD88 deficiency. Which TLR would still function relatively normally, and why?

4. Compare and contrast how the immune system distinguishes bacterial DNA from host DNA using TLR9. What molecular feature is the key discriminator?

5. Trace the pathway from TLR3 activation to the establishment of an antiviral state in neighboring cells. What are the key signaling intermediates and effector molecules?

6. Why are the endosomal TLRs (TLR3, 7, 8, 9) located inside the cell rather than on the surface? What problem does this compartmentalization solve?